ArticleAnnals of hematology2026

Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study.

Yun Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.